yesterday fda approv background link discuss increment
detail call morn ultim news make us confid
room potenti materi upsid revenu expect also
feel better price biggest stock overhang expect number go higher
narr begin improv p-t
special control criteria manag provid ton specif special
control criteria fda expect implement per fda control outlin
requir assur icgm devic accuraci reliabl clinic relev
 importantli describ type studi data requir demonstr
accept icgm perform detail new product class reduc
classif class ii see note yesterday link
manag provid ton detail say fda set
rigor bar bar high bar perform outlier includ day
notabl differenti may compani
classif near medium term futur enabl faster innov
wait see fda say
automat shut manag announc icgm includ requir
automat shut label day us longer day
label shorter estim averag patient use sensor
day ultim averag expect chang result patient purchas
sensor current per year manag discuss price
thought implic
launch time manag expect begin us shipment late though exact
time detail provid assum shipment fairli modest
broad launch come beyond expect launch ou
pipelin manag note day version come least
need accru data product ensur meet new special control
criteria ultim believ new classif fda enabl
partner move faster await detail verili plan product
partner earn call
three import point make competit perspect
clearli best product alway believ like
becom consensu automat shut price
 see recent survey link even respond assum cost
pocket compani expect remain clear market leader expect
libr well libr well mutual exclus market
acceler best product
pleas see page report import disclosur
believ make core growth stori attract
market dynam technolog differenti top-tier manag team
scalabl profit model competit potenti longer term price headwind
exist howev best pipelin industri believ remain clear
market leader forese futur wherev market goe
regulatori commerci mileston
us type cgm penetr continu
rapidli increas toward
revenu growth approxim
thereaft
cgm penetr continu rapidli
increas toward standard care us
cgm begin adopt
revenu growth acceler
cgm penetr slow fail progress
toward standard care
price deterior faster expect
found headquart san diego california medic devic
compani focus design develop commerci continu glucos
monitor cgm system use peopl diabet use healthcar
provid hospit treatment patient without diabet dexcom
flagship offer today dexcom mobil patient diabet detect
trend track glucos pattern fda approv pediatr patient adult
move forward compani focus continu drive advanc cgm
technolog focus accuraci comfort connect longer term dexcom
goal replac tradit blood glucos monitor technolog
note automat shutoff like drive patient purchas
sensor averag current manag discuss price
howev chang day label potenti make receiv
option current medicar payment rate believ room price
ultim arriv expect albeit current level remind
made signific downward revis price forecast part januari
survey link effort conserv possibl price given uncertainti
creat launch libr continu believ price come
time increasingli believ assumpt may conserv
point signific revenu implic appear reflect
consensu expect updat model today
high convict room upsid revenu expect
potenti signific upsid could much upsid
expect though clearli detail still learn increas
price target base dcf analysi repres upsid
revenu estim multipl previous use dcf analysi
still includ contribut broader type opportun toward
progress clearli made link link remain long term believ
clear think short thesi compel near term
room upsid number potenti shift stock narr march
total share outstand short
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
medic suppli devic diabet
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
medic suppli devic diabet
risk diabet devic sector may includ regulatori process potenti delay
commerci launch new product potenti price pressur payor/cm
premium rel valuat competit high level invest need compet
make invest recommend earli stage diabet devic compani base
upon assess technolog probabl market success competit
regulatori reimburs etc potenti market opportun event
success howev compani lack tradit and/or matur financi
metric believ specif methodolog assign price target
risk includ limit cgm penetr fail increas competit product
reduc competit moat profit push back materi new product
releas delay due regulatori hurdl trade signific premium
